Drug Information

Drug General Information
Drug ID
D07AIB
Former ID
DNC003513
Drug Name
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [525876]
Formula
C20H15N3O
Canonical SMILES
C1=CC=C(C=C1)OC2=CC=C(C=C2)NC3=NC=NC4=CC=CC=C43
InChI
1S/C20H15N3O/c1-2-6-16(7-3-1)24-17-12-10-15(11-13-17)23-20-18-8-4-5-9-19(18)21-14-22-20/h1-14H,(H,21,22,23)
InChIKey
RJOICMFRJBMONF-UHFFFAOYSA-N
PubChem Compound ID
712152
Target and Pathway
Target(s) Angiopoietin 1 receptor Target Info Inhibitor [525876]
Vascular endothelial growth factor receptor 2 Target Info Inhibitor [525876]
Lck tyrosine kinase Target Info Inhibitor [525876]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Rheumatoid arthritishsa04014:Ras signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancerhsa04064:NF-kappa B signaling pathway
Osteoclast differentiation
Natural killer cell mediated cytotoxicity
T cell receptor signaling pathway
HTLV-I infection
Primary immunodeficiency
NetPath Pathway Wnt Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
IL2 Signaling Pathway
PANTHER Pathway AngiogenesisP00005:Angiogenesis
VEGF signaling pathwayP00049:Parkinson disease
T cell activation
Pathway Interaction Database Angiopoietin receptor Tie2-mediated signaling
SHP2 signalinghif2pathway:HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networknfkappabatypicalpathway:Atypical NF-kappaB pathway
Glypican 1 network
TCR signaling in na&#xef
Signaling events mediated by PTP1B
IL12-mediated signaling events
Regulation of p38-alpha and p38-beta
TCR signaling in na&#xef
Thromboxane A2 receptor signaling
IL2-mediated signaling events
CXCR4-mediated signaling events
Class I PI3K signaling events
IL2 signaling events mediated by PI3K
amb2 Integrin signaling
EPHA forward signaling
PDGFR-beta signaling pathway
IL2 signaling events mediated by STAT5
Ephrin B reverse signaling
Alpha-synuclein signaling
Reactome Tie2 Signaling
RAF/MAP kinase cascadeR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-114604:GPVI-mediated activation cascade
PIP3 activates AKT signaling
Regulation of KIT signaling
Phosphorylation of CD3 and TCR zeta chains
Translocation of ZAP-70 to Immunological synapse
Generation of second messenger molecules
PECAM1 interactions
Constitutive Signaling by Aberrant PI3K in Cancer
DAP12 signaling
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
CD28 dependent Vav1 pathway
CTLA4 inhibitory signaling
PD-1 signaling
Interleukin-2 signaling
WikiPathways Wnt Signaling Pathway Netpath
Cell surface interactions at the vascular wall
AngiogenesisWP306:Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
AngiogenesisWP61:Notch Signaling Pathway
Interferon type I signaling pathways
IL-2 Signaling Pathway
Inflammatory Response Pathway
Signaling by SCF-KIT
DAP12 interactions
Host Interactions of HIV factors
PIP3 activates AKT signaling
T-Cell Receptor and Co-stimulatory Signaling
B Cell Receptor Signaling Pathway
TSLP Signaling Pathway
TCR signaling
Costimulation by the CD28 family
References
Ref 525876Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
Ref 525876Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.